BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors.
Rujiao Liu, Hui Jing, Yang Chen, Shuiping Gao, Jinghao Zhang, Xubo Cao, Ke Li, Yuanyuan Liu, Meng Meng, Cong Chen, Ci Sun, Haoyu Yu, Qingyu Wang, Jing Li, Yanmin Wu
Published: 202610.1007/s40259-025-00751-z
Abstract
BACKGROUND: HLX26 is a novel, recombinant humanized anti-LAG-3 IgG4 monoclonal antibody that exhibits high affinity for LAG-3 and demonstrates that it can block LAG-3 and its ligand interaction and activate T cells in preclinical in vitro studies. OB…
Preview only. Read the full abstract at the source